Bullish
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating
Oppenheimer has increased its price target for Protara Therapeutics (TARA) to $28 from $25, while reiterating an Outperform rating on the stock. This ...
